Wikipedia is running out of money. But instead of accepting ads it will pull the plug if it doesn't receive enough donations to keep it going. Which means that the founders will put to sleep the fastest growing common grounds for sharing information around the globe out of principle.
http://www.calacanis.com/2007/02/10/wikipedias-got-3-4-months-to-live-and-wikipedias-technolo/
Sounds a lot like the purists who continue to seek a purge of all industry "sponsored" support of any kind of any medical research or activity. At some point the lack of commercial investment and the possibility of return will cause new information to dry up.
Non-profits and generic firms have much difference incentives. They don't need to "market" new medicines or even want to. They spend very little here or overseas training or explaining to doctors how to use drugs. You won't see Teva investing in new uses for the generic form of Lovenox (regardless of how valid it's recent patent challenge might be) . And you would not see them invest any time or money in putting together the efficacy and safety data for a priority review of a new indication as Sanofi did.
http://www.pharmaceutical-business-review.com/article_news.asp?guid=DDDCA11E-497B-4979-A659-B8759752875E
The zealots don't care, either because they are healthy (and don't care about the need to commercialize innovation) or driven by drug company hatred. That's a disease too.
http://www.calacanis.com/2007/02/10/wikipedias-got-3-4-months-to-live-and-wikipedias-technolo/
Sounds a lot like the purists who continue to seek a purge of all industry "sponsored" support of any kind of any medical research or activity. At some point the lack of commercial investment and the possibility of return will cause new information to dry up.
Non-profits and generic firms have much difference incentives. They don't need to "market" new medicines or even want to. They spend very little here or overseas training or explaining to doctors how to use drugs. You won't see Teva investing in new uses for the generic form of Lovenox (regardless of how valid it's recent patent challenge might be) . And you would not see them invest any time or money in putting together the efficacy and safety data for a priority review of a new indication as Sanofi did.
http://www.pharmaceutical-business-review.com/article_news.asp?guid=DDDCA11E-497B-4979-A659-B8759752875E
The zealots don't care, either because they are healthy (and don't care about the need to commercialize innovation) or driven by drug company hatred. That's a disease too.
